acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide

01/01/2018 - "Degarelix is effective in the treatment of prostate cancer. "
04/01/2013 - "Degarelix provides a cost-effective treatment for ADT among patients with locally advanced prostate cancer."
12/01/2009 - "Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer."
06/01/2023 - "Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer."
06/01/2023 - "Conclusions Our study suggests that neoadjuvant degarelix could notably enhance patient outcomes in locally advanced prostate cancer management. "

03/01/2013 - "The added benefits of degarelix in terms of more pronounced lower urinary tract symptom relief in symptomatic patients could be the reflection of differences in the direct effects on extra-pituitary receptors in the lower urinary tract [Clinicaltrials.gov ID: NCT00833248]."
12/01/2012 - "Degarelix treatment evokes, however, significantly better relief of lower urinary tract symptoms in patients having moderate and severe voiding problems. "
01/01/2014 - "We performed a systematic review and meta-analysis to assess the efficacy and tolerability of degarelix for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer (PCa). "
07/01/2012 - "[The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer]."
01/01/2013 - "No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa). "

07/05/2021 - "This is a randomized phase 2, placebo-controlled, double-blind clinical trial in 198 patients to compare efficacy of degarelix plus best supportive care versus placebo plus best supportive care on improving the clinical outcomes of male Veterans who have been hospitalized due to COVID-19. "
07/05/2021 - "Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial."
01/01/2022 - "The Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) phase 2, placebo-controlled, double-blind, randomized clinical trial compared efficacy of degarelix plus standard care vs placebo plus standard care on clinical outcomes in men hospitalized with COVID-19 but not requiring invasive mechanical ventilation. "
01/01/2022 - "In this randomized clinical trial of androgen suppression vs placebo and usual care for men hospitalized with COVID-19, degarelix did not result in amelioration of COVID-19 severity. "
01/01/2022 - "To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19. "

01/01/2021 - "He had degarelix injection, and the choroidal tumor resolved rapidly and became flat degeneration in a month. "
01/01/2021 - "FSH supplementation reversed the degarelix-evoked suppression of PC-3 tumors, both in preventive (degarelix and FSH treatment started upon cell inoculation) and therapeutic (treatments initiated 3 weeks after cell inoculation) setting. "
01/01/2021 - "All tumors expressed GnRHR and FSHR, and degarelix treatment suppressed their growth. "
01/01/2018 - "Compared with either ADT or VTP alone, a single dose of degarelix in concert with VTP significantly inhibited tumor growth. "
03/01/2007 - "In both studies, degarelix demonstrated a sustained inhibition of tumor growth at least comparable with surgical castration. "

11/01/2011 - "First time cardiovascular disease events were reported in 92 men in the year before study entry and in 168 after degarelix treatment. "
11/01/2011 - "Degarelix dose and schedule were not independently associated with cardiovascular disease events. "
11/01/2011 - "In contrast, event rates appeared higher after degarelix treatment in men with cardiovascular disease at baseline (5.3 to 10.5 events per 100 person-years, p = 0.0013). "
11/01/2011 - "Event rates were similar before and after degarelix treatment in the total population (5.5 vs 6.1/100 person-years, p = 0.45) and in men without cardiovascular disease (5.6 vs 4.3/100 person-years, p = 0.11). "
11/01/2011 - "In men with prostate cancer observed rates of cardiovascular disease events were similar before and after degarelix treatment. "